BioCentury | Feb 4, 2021
Finance

Muted reception for Sensei, Landos on NASDAQ as more biotechs set to leap into public markets

...Landos said the treatment showed a positive trend toward remission rates vs. placebo.Sensei’s underwriters are Citigroup...
BioCentury | Nov 6, 2020
Management Tracks

BeiGene’s pathfinding CFO Liang to retire

...HKEX:2552), which hired George Lin from Bank of America; and Zai Lab Ltd. (NASDAQ:ZLAB), which hired Citigroup’s...
BioCentury | Jun 3, 2020
Finance

Third Rock-launched Pliant is latest biotech to climb on public debut

...Co. Ltd., Lantern Pharma Inc. and Applied Molecular Transport Inc. (see “IPO Queue Grows” ). Citigroup...
...Pliant’s deal. Targets CD51 (CD29) - Integrin α(V)β(1) Danielle Kopke, Staff Writer PLN-1474 PLN-74809 Pliant Therapeutics Inc. Novartis AG Third Rock Ventures Citigroup Cowen Piper...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...and Trikafta elexacaftor/tezacaftor/ivacaftor. Royalty Pharma's underwriters are J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup...
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

...Allergan plc, now part of AbbVie Inc. (NYSE:ABBV), following its acquisition of Tobira Therapeutics Inc. Citigroup...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

...Column Group, Topspin Partners, OrbiMed Advisors and EcoR1 Capital. The offering’s underwriters are J.P. Morgan, Citigroup...
BioCentury | Feb 18, 2020
Finance

Feb. 18 Financial Quick Takes: Imara's IPO filing, Passage's terms, and fundings for OMass and Univercells

...disorder and β-thalassemia. The company has raised $77.3 million since its 2016 inception. Morgan Stanley, Citigroup...
BioCentury | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

...market close, Apellis proposed the sale of 7 million shares in a follow-on underwritten by Citigroup...
BioCentury | Dec 6, 2019
Financial News

Financing Roundup: Immunomedics, Ardelyx, Millendo, Omeros, Athenex

...million shares at $6.25 a share, raising $125 million at an 8% discount. Underwriters were Citigroup...
...million shares at $6 a share to raise $25 million. The transaction was underwritten by Citigroup...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...Quintuples in Value as Schizophrenia Combo Clears Phase II Bar" ). Underwriters are Goldman Sachs, Citigroup...
Items per page:
1 - 10 of 864
BioCentury | Feb 4, 2021
Finance

Muted reception for Sensei, Landos on NASDAQ as more biotechs set to leap into public markets

...Landos said the treatment showed a positive trend toward remission rates vs. placebo.Sensei’s underwriters are Citigroup...
BioCentury | Nov 6, 2020
Management Tracks

BeiGene’s pathfinding CFO Liang to retire

...HKEX:2552), which hired George Lin from Bank of America; and Zai Lab Ltd. (NASDAQ:ZLAB), which hired Citigroup’s...
BioCentury | Jun 3, 2020
Finance

Third Rock-launched Pliant is latest biotech to climb on public debut

...Co. Ltd., Lantern Pharma Inc. and Applied Molecular Transport Inc. (see “IPO Queue Grows” ). Citigroup...
...Pliant’s deal. Targets CD51 (CD29) - Integrin α(V)β(1) Danielle Kopke, Staff Writer PLN-1474 PLN-74809 Pliant Therapeutics Inc. Novartis AG Third Rock Ventures Citigroup Cowen Piper...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...and Trikafta elexacaftor/tezacaftor/ivacaftor. Royalty Pharma's underwriters are J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup...
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

...Allergan plc, now part of AbbVie Inc. (NYSE:ABBV), following its acquisition of Tobira Therapeutics Inc. Citigroup...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

...Column Group, Topspin Partners, OrbiMed Advisors and EcoR1 Capital. The offering’s underwriters are J.P. Morgan, Citigroup...
BioCentury | Feb 18, 2020
Finance

Feb. 18 Financial Quick Takes: Imara's IPO filing, Passage's terms, and fundings for OMass and Univercells

...disorder and β-thalassemia. The company has raised $77.3 million since its 2016 inception. Morgan Stanley, Citigroup...
BioCentury | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

...market close, Apellis proposed the sale of 7 million shares in a follow-on underwritten by Citigroup...
BioCentury | Dec 6, 2019
Financial News

Financing Roundup: Immunomedics, Ardelyx, Millendo, Omeros, Athenex

...million shares at $6.25 a share, raising $125 million at an 8% discount. Underwriters were Citigroup...
...million shares at $6 a share to raise $25 million. The transaction was underwritten by Citigroup...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...Quintuples in Value as Schizophrenia Combo Clears Phase II Bar" ). Underwriters are Goldman Sachs, Citigroup...
Items per page:
1 - 10 of 864